Literature DB >> 28242663

Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.

Geetha Ramachandran1, Hemanth Kumar Agibothu Kupparam2, Chandrasekaran Vedhachalam2, Kannan Thiruvengadam2, Vijayalakshmi Rajagandhi2, Azger Dusthackeer2, Ramesh Karunaianantham2, Lavanya Jayapal3, Soumya Swaminathan2.   

Abstract

The Indian Revised National Tuberculosis (TB) Control Programme uses thrice-weekly treatment with standard drug dosages. The role of plasma drug levels and other factors in determining TB treatment outcomes is not well understood. We aimed to determine the factors influencing the concentrations of rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA) at 2 h postdosing in adult TB patients and to study the factors impacting TB treatment outcome. We recruited 1,912 adult TB patients (newly treated and retreated patients) with pulmonary/extrapulmonary TB receiving antitubercular treatment (ATT) in the RNTCP in Chennai, India. At steady state, the concentrations of RMP, INH, and PZA were determined at 2 h postdosing after supervised drug administration. A total of 1,648 patients had a favorable outcome, while 264 (14%) had an unfavorable outcome. A total of 91%, 16%, and 17% of the patients had suboptimal concentrations of RMP (<8 μg/ml), INH (<3 μg/ml), and PZA (<20 μg/ml), respectively. Factors associated with treatment outcome were low RMP concentrations (adjusted odds ratio [aOR], 0.94; 95% confidence interval [CI], 0.89 to 0.99; P = 0.036), category II ATT (aOR, 2.39; 95% CI, 1.56 to 3.65; P < 0.001), low body weight (aOR, 0.96; 95% CI, 0.94 to 0.98; P < 0.001), alcohol use (aOR, 2.17; 95% CI, 1.42 to 3.31; P < 0.001), male gender (aOR, 1.92; 95% CI, 1.02 to 3.62; P = 0.043), and baseline INH resistance (aOR, 5.74; 95% CI, 3.12 to 10.59; P < 0.001), which significantly increased the likelihood of an unfavorable outcome in multivariate logistic regression analysis. Further studies are needed to optimize anti-TB drug dosages and improve cure rates. Drug susceptibility testing at the baseline and attention to undernutrition and alcohol dependence are other important interventions.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  isoniazid; pharmacokinetics; pyrazinamide; rifampin; treatment outcome; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28242663      PMCID: PMC5404592          DOI: 10.1128/AAC.02464-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

Authors:  Marc Weiner; William Burman; Andrew Vernon; Debra Benator; Charles A Peloquin; Awal Khan; Stephen Weis; Barbara King; Nina Shah; Thomas Hodge
Journal:  Am J Respir Crit Care Med       Date:  2003-01-16       Impact factor: 21.405

2.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy.

Authors:  J B Mehta; H Shantaveerapa; R P Byrd; S E Morton; F Fountain; T M Roy
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

3.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors:  Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal:  Clin Infect Dis       Date:  2005-04-14       Impact factor: 9.079

5.  Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.

Authors:  Jordan W Tappero; Williamson Z Bradford; Tracy B Agerton; Philip Hopewell; Arthur L Reingold; Shahin Lockman; Aderonke Oyewo; Elizabeth A Talbot; Thomas A Kenyon; Themba L Moeti; Howard J Moffat; Charles A Peloquin
Journal:  Clin Infect Dis       Date:  2005-07-08       Impact factor: 9.079

6.  Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors.

Authors:  M Narita; M Hisada; B Thimmappa; J Stambaugh; E Ibrahim; E Hollender; D Ashkin
Journal:  Clin Infect Dis       Date:  2001-01-25       Impact factor: 9.079

7.  Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000.

Authors:  T Santha; R Garg; T R Frieden; V Chandrasekaran; R Subramani; P G Gopi; N Selvakumar; S Ganapathy; N Charles; J Rajamma; P R Narayanan
Journal:  Int J Tuberc Lung Dis       Date:  2002-09       Impact factor: 2.373

8.  Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid.

Authors:  J Ray; I Gardiner; D Marriott
Journal:  Intern Med J       Date:  2003 May-Jun       Impact factor: 2.048

9.  Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

Authors:  A Jindani; A J Nunn; D A Enarson
Journal:  Lancet       Date:  2004 Oct 2-8       Impact factor: 79.321

10.  Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

Authors:  R van Crevel; B Alisjahbana; W C M de Lange; F Borst; H Danusantoso; J W M van der Meer; D Burger; R H H Nelwan
Journal:  Int J Tuberc Lung Dis       Date:  2002-06       Impact factor: 2.373

View more
  13 in total

Review 1.  Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review.

Authors:  Noor Ul Ain Shahid; Noreen Naguit; Rakesh Jakkoju; Sadia Laeeq; Tiba Reghefaoui; Hafsa Zahoor; Ji Hyun Yook; Muneeba Rizwan; Lubna Mohammed
Journal:  Cureus       Date:  2022-05-17

2.  Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study.

Authors:  Addisu Getie; Birhan Alemnew
Journal:  Infect Drug Resist       Date:  2020-10-06       Impact factor: 4.003

3.  Treatment outcome of tuberculosis patient of Samtse General Hospital, Bhutan.

Authors:  Thinley Dorji; Kinley Wangdi
Journal:  Nepal J Epidemiol       Date:  2020-09-30

Review 4.  Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.

Authors:  Lauren S Peetluk; Felipe M Ridolfi; Peter F Rebeiro; Dandan Liu; Valeria C Rolla; Timothy R Sterling
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

5.  Is a differentiated care model needed for patients with TB? A cohort analysis of risk factors contributing to unfavourable outcomes among TB patients in two states in South India.

Authors:  Reynold Washington; Rajaram Subramanian Potty; A Rajesham; T Seenappa; Anil Singarajipura; Reuben Swamickan; Amar Shah; K H Prakash; Arin Kar; Karthikeyan Kumaraswamy; B S Prarthana; Bala Krishna Maryala; J Sushma; Ramesh Dasari; Bharath Shetty; Vikas Panibatla; H L Mohan; Marissa Becker
Journal:  BMC Public Health       Date:  2020-07-24       Impact factor: 3.295

6.  Treatment outcomes of patients with tuberculosis in war affected region of Khyber Pakhtunkhwa, Pakistan.

Authors:  Tauseef Ahmad; Muhammad Ayub Jadoon; Muhammad Khan; Muhammad Mumtaz Khan; Akbar Hussain; Taha Hussein Musa; Muhammad Waqar; Eyasu Ejeta; Manoochehr Karami; Kefyalew Addis Alene; Hui Jin
Journal:  BMC Infect Dis       Date:  2020-07-01       Impact factor: 3.090

Review 7.  Sexual dimorphism in bacterial infections.

Authors:  Edgar Ricardo Vázquez-Martínez; Elizabeth García-Gómez; Ignacio Camacho-Arroyo; Bertha González-Pedrajo
Journal:  Biol Sex Differ       Date:  2018-06-20       Impact factor: 5.027

8.  Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.

Authors:  Bibie N Said; Scott K Heysell; Getnet Yimer; Rob E Aarnoutse; Gibson S Kibiki; Stellah Mpagama; Peter M Mbelele
Journal:  Int J Mycobacteriol       Date:  2021 Oct-Dec

9.  Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.

Authors:  Agibothu Kupparam Hemanth Kumar; Vedachalam Chandrasekaran; Angadi Kiran Kumar; M Kawaskar; J Lavanya; Soumya Swaminathan; Geetha Ramachandran
Journal:  Indian J Med Res       Date:  2017-04       Impact factor: 2.375

10.  Factors associated with hospitalization and death among TB/HIV co-infected persons in Porto Alegre, Brazil.

Authors:  Maíra Rossetto; Évelin Maria Brand; Renata Mendonça Rodrigues; Laura Serrant; Luciana Barcellos Teixeira
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.